OncoCyte Corporation (OCX)
Market Cap | 39.56M |
Revenue (ttm) | 1.38M |
Net Income (ttm) | -40.86M |
Shares Out | 13.36M |
EPS (ttm) | -5.08 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 44,533 |
Open | 2.850 |
Previous Close | 2.950 |
Day's Range | 2.810 - 3.060 |
52-Week Range | 2.080 - 4.860 |
Beta | 0.83 |
Analysts | Buy |
Price Target | 4.06 (+37.16%) |
Earnings Date | Aug 8, 2024 |
About OCX
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design an... [Read more]
Financial Performance
In 2023, OncoCyte's revenue was $1.50 million, an increase of 56.89% compared to the previous year's $958,000. Losses were -$28.72 million, -60.88% less than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for OCX stock is "Buy." The 12-month stock price forecast is $4.06, which is an increase of 37.16% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/1/d/press4-2493376.jpg)
Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leader within the financial markets and news community, announces the release of an article highlighting the precision diagnostics compa...
![](https://cdn.snapi.dev/images/v1/r/1/press7-2455106.jpg)
Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
IRVINE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that favorable data regarding its lead product VitaGraft™ Kidney ...
![](https://cdn.snapi.dev/images/v1/g/h/press16-2433279.jpg)
Oncocyte Reports First Quarter 2024 Financial Results
IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024.
![](https://cdn.snapi.dev/images/v1/l/m/press9-2368700.jpg)
Oncocyte Reports Full Year 2023 Financial Results
IRVINE, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023.
![](https://cdn.snapi.dev/images/v1/b/u/conf12-2364040.jpg)
Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results
IRVINE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will release its fourth quarter and full year 2...
![](https://cdn.snapi.dev/images/v1/c/y/press1-1986393.jpg)
VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients
- Blood-based test differentiates between ABMR and IgAN, enabling faster and more effective treatment- Improved utility over standard of care tests- Paper published in peer-reviewed journal
![](https://cdn.snapi.dev/images/v1/a/c/press11-1984897.jpg)
Oncocyte Announces 1-For-20 Reverse Stock Split
IRVINE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (the “Company”), a precision diagnostics company, announced today that the Company will implement a 1-for-20 revers...
![](https://cdn.snapi.dev/images/v1/3/m/press14-1949414.jpg)
Oncocyte Begins Manufacturing Transplant Blood Test
Over 1 million annual testing opportunities in US Q4 targeted for early access launch IRVINE, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics comp...
![](https://cdn.snapi.dev/images/v1/n/g/conf6-1917610.jpg)
Oncocyte Corporation to Present at the LD Micro Invitational XIII
Irvine, California--(Newsfile Corp. - June 1, 2023) - Oncocyte Corporation (NASDAQ: OCX) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevar...
![](https://cdn.snapi.dev/images/v1/f/i/press8-1884837.jpg)
Oncocyte Reports First Quarter 2023 Financial Results
IRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the first quarter 2023, ended March 31, 2023...
![](https://cdn.snapi.dev/images/v1/j/c/conf17-1859538.jpg)
Oncocyte To Announce First Quarter 2023 Financial Results
IRVINE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it will release its first quarter 2023 financial results on...
![](https://cdn.snapi.dev/images/v1/y/h/press7-1841373.jpg)
Oncocyte Presents New Data at AACR
IRVINE, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that five posters of original research are being presented at t...
![](https://cdn.snapi.dev/images/v1/n/o/press10-1834977.jpg)
Oncocyte Announces Reduction in Force
IRVINE, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a reduction in force involving approximately 20% of its workforc...
![](https://cdn.snapi.dev/images/v1/o/j/press13-1829491.jpg)
Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer
IRVINE, Calif., April 07, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostic company, today announces the peer-reviewed publication of the results of a study applying ...
![](https://cdn.snapi.dev/images/v1/a/0/press19-1821753.jpg)
Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K
IRVINE, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced plans to file a Form 12b-25 with the U.S. Securities and Exchang...
![](https://cdn.snapi.dev/images/v1/l/h/conf17-1817831.jpg)
Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call
IRVINE, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it has changed the date of its previously announced earning...
![](https://cdn.snapi.dev/images/v1/w/g/conf9-1798857.jpg)
Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results
IRVINE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it will release its fourth quarter and full year 2022 finan...
![](https://cdn.snapi.dev/images/v1/a/v/press20-1779387.jpg)
Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer
IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that Joshua Riggs has been appointed as its Chief Executive Offi...
![](https://cdn.snapi.dev/images/v1/2/e/press4-1764750.jpg)
Oncocyte Completes Razor Genomics Transaction
Company retains 30% stake while eliminating operating expense and future development obligations Represents next step in plan to focus product strategy
![](https://cdn.snapi.dev/images/v1/v/g/biotech32-1678420.jpg)
Oncocyte cuts 40% of staff
Oncocyte Corp. shares rose 5% in premarket trades after the Irvine, Calif., molecular diagnostics company for the detection of cancer, said it would reduce more than 40% of its workforce "to align its...
![](https://cdn.snapi.dev/images/v1/z/0/press17-1678371.jpg)
Oncocyte Announces Initiatives to Focus Corporate Strategy
IRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a reduction in force involving over 40% of Oncocyte's workforce t...
![](https://cdn.snapi.dev/images/v1/v/n/press17-1657770.jpg)
Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors
IRVINE, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights th...
![](https://cdn.snapi.dev/images/v1/v/8/press14-1657761.jpg)
Oncocyte Announces Executive Leadership Changes
IRVINE, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights th...
![](https://cdn.snapi.dev/images/v1/f/o/press19-1631581.jpg)
Oncocyte Reports Third Quarter 2022 Financial Results
IRVINE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights th...
![](https://cdn.snapi.dev/images/v1/n/3/conf9-1604214.jpg)
Oncocyte to Announce Third Quarter 2022 Financial Results
IRVINE, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights th...